Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
CONCLUSION: This real-world study revealed that one-third of the patients received sequential CDK4/6i after ET + palbociclib, and treatment duration of ET + CDK4/6i following ET + palbociclib was the longest among the treatment options. Further data are awaited to determine whether ET + targeted therapy with CDK4/6i and mTORi provides acceptable treatment options following ET + palbociclib.PMID:37267715 | DOI:10.1016/j.breast.2023.05.006
Source: Breast - Category: Cancer & Oncology Authors: Masataka Sawaki Yasuaki Muramatsu Kanae Togo Hiroji Iwata Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Endocrine Therapy | Japan Health | Study | Togo Health